Success Metrics

Clinical Success Rate
90.9%

Based on 10 completed trials

Completion Rate
91%(10/11)
Active Trials
0(0%)
Results Posted
40%(4 trials)
Terminated
1(9%)

Phase Distribution

Ph not_applicable
5
45%
Ph phase_4
4
36%
Ph phase_2
1
9%
Ph phase_1
1
9%

Phase Distribution

1

Early Stage

1

Mid Stage

4

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
1(9.1%)
Phase 2Efficacy & side effects
1(9.1%)
Phase 4Post-market surveillance
4(36.4%)
N/ANon-phased studies
5(45.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

90.9%

10 of 11 finished

Non-Completion Rate

9.1%

1 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(10)
Terminated(1)

Detailed Status

Completed10
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
90.9%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (9.1%)
Phase 21 (9.1%)
Phase 44 (36.4%)
N/A5 (45.5%)

Trials by Status

completed1091%
terminated19%

Recent Activity

Clinical Trials (11)

Drug Details

Intervention Type
DRUG
Total Trials
11